Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 4
- 主要终点
- Assessment of Disease Activity
研究概览
简要总结
Crohn's disease is a chronic inflammatory condition of the intestines that causes abdominal pain, diarrhea, tunnels around the anus (fistulas), and extraintestinal symptoms. Effective medical treatments exist to treat the disease; however they can have significant side effects.
Previous studies have shown that sexual function is impaired in patients with Crohn's disease. It is likely that both the symptoms related to the disease, medications used to treat the disease, and surgery all impair sexual function in a variety of ways. For example, body image may be impaired, patients may be worried about bowel incontinence or unpleasant odors associated with diarrhea, patients may have significant pelvic pain secondary to perianal fistulas, or they may have painful intercourse from adjacent inflammation or scarring in the pelvis. The impact of medical treatment on patient's ability to regain sexual function is not known.
The investigators propose a 6 month study to compare sexual function before and after treatment in patients with Crohn's disease about to initiate therapy with an anti-TNF drug for treatment of perianal fistula or intestinal Crohn's or about to initiate therapy with steroids.
The investigators anticipate that the investigators will show that therapy with an anti TNF agent will result in a more rapid and greater return of sexual function than steroids. This information will be important to help counsel patients about the optimal treatment to begin for treatment of their Crohn's disease. Furthermore, it would be the first study to evaluate the impact of medical therapy on sexual function.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of Crohn's disease confirmed by standard criteria
- •Active luminal Crohn's disease defined by an HBI score of >4 or with draining perianal Crohn's disease a) Active perianal Crohn's disease defined a presence of draining perianal fistula on physical exam19
- •Patients with active luminal Crohn's disease must be initiating treatment with an anti-TNF agent (Remicade, Humira, Cimzia, or Simponi) or a steroid (prednisone, Entocort, or Uceris).
- •Patients with active perianal disease must be initiating therapy with an anti-TNF agent (Remicade, Humira, Cimzia, or Simponi).
- •Can understand written instructions in English
排除标准
- •Previous primary non-response to an anti-TNF
- •Uncontrolled medical or psychiatric disease (a. Degenerative neurologic condition, b.Unstable angina, c.Class III/IV congestive heart failure, d.Severe asthma or chronic obstructive pulmonary disease, e.Symptomatic peripheral vascular disease, f. Chronic renal insufficiency (creatinine > 2.0), g. Malignancy within the last 3 years (excluding squamous or basal cell cancers of the skin), h. Poorly controlled depression, mania, and schizophrenia, i. Active infection, j. Acquired immunodeficiency syndrome)
- •Inability to adhere to the protocol
- •Need for imminent surgery other than an exam under anesthesia
- •Under 18 years of age.
- •Pregnancy
- •Use of concurrent prednisone >30 mg per day in the anti-TNF groups
研究组 & 干预措施
Anti-TNF (Remicade, Humira or Cimzia) for luminal CD
All participants are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
干预措施: Anti-TNF (Drug)
Anti-TNF (Remicade, Humira or Cimzia)for perianal CD
All participants are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
干预措施: Anti-TNF (Drug)
Steroid (Prednisone or budesonide) for luminal CD
All participants are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
干预措施: Steroids (Drug)
结局指标
主要结局
Assessment of Disease Activity
时间窗: 6 months
Harvey Bradshaw Index
Assessment of Quality of Life
时间窗: 6 months
Short Inflammatory Bowel Disease Questionnaire
Assessment of Body Image
时间窗: 6 months
Body Image Scale
Assessment of Perianal Disease Activity
时间窗: 6 months
Perianal Disease Activity Index
Assessment of Sexual Function
时间窗: 6 months
Sexual Function Questionnaire
Assessment of Depression
时间窗: 6 months
PHQ 9
次要结局
未报告次要终点
研究者
Raymond Cross
Professor of Medicine
University of Maryland, Baltimore